An ancillary study of 'Investigation of efficacy of nivolumab in patients with recurrent and refractory peripheral T cell lymphoma: Investigator initiated phase 2 clinical trial'

An ancillary study of 'Investigation of efficacy of nivolumab in patients with recurrent and refractory peripheral T cell lymphoma: Investigator initiated phase 2 clinical trial' - W-JHS NHL02-A study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034502

Enrollment

Registered

2018-10-15

Start date

2018-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral T cell lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients enrolled in W-JHS NHL02 2)Patients providing the written informed consent. 3)Patients whose specimens for any test in 'biomarker exploration' can be submitted

Exclusion criteria

Exclusion criteria: Nothing particular

Design outcomes

Primary

Measure	Time frame
gene and protein expression, gene mutation, lymphocyte subset analysis, serum cytokine and chemokine, HLA gene, single cell analysis	—

Countries

Japan

Contacts

Public ContactKoji Kato

Kyushu University Hospital Department of Hematology, Oncology and Cardiovascular Medicine

kojikato@intmed1.med.kyushu-u.ac.jp092-642-5230

Outcome results